BEAM - Intellia's Bold Bet Pays Off Justifying Its Valuation
- CRISPR biotech companies have been showing promising clinical trial data, validating the technology as a disruptive force within the industry, pushing the sector's shares higher.
- NTLA's bold bet on its LNP delivery system paid off, expanding CRISPR applications beyond the Hematologic space, adding a competitive moat, and enhancing its commercial prospects, contributing to its valuation.
- NTLA will probably issue more shares, raising capital to fund its pipeline. However, from now on, new capital raises will be less dilutive given the ticker's recent rally.
For further details see:
Intellia's Bold Bet Pays Off, Justifying Its Valuation